Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release.
Epistemonikos ID: 9aeeb8142aee32e5c95c9f3265b539df5e139358
First added on: May 11, 2024